If you’re unfamiliar with Mikhail Blagosklonny, he is the Editor-in-Chief of Oncotarget, an open-access medical journal with an emphasis on oncology (a branch of science focused on tumors and cancers). Additionally, and most notably, Blagosklonny is a professor of Oncology at the famed Roswell Park Cancer Institute, based in New York. Blagosklonny has received critical acclaim for his many contributions in the field of oncology; his research has led to the publication of articles explaining how the human body’s innate ability to rejuvenate cells can mitigate the preponderance of cancer in seniors. In these articles, Blagosklonny also explains the relationship between TOR signaling and aging, which suggest the possibility of using the immunosuppressant drug Rapamycin in cancer treatment.
Blagosklonny attended First Pavlov State Medical University (a College in Saint Petersburg, Russia) where he earned an MD in internal medicine and a Ph.D. in experimental medicine and cardiology. Prior to becoming an oncology professor with Roswell Park Cancer Institue in 2009, Blagosklonny served as an associate professor at New York Medical College and was also a senior scientist at Ordway Research Institute, based in Albany, New York. Mikhail Blagosklonny’s work in cancer research and anti-aging is comprised of cancer therapies that protect cells and promote biogerontology, which is a special field of science that explains gerontology. These studies have led to the potential alternative use of Rapamycin in not only cancer treatment, but also as a drug therapy that could possibly boost the body’s immune system.Blagosklonny has been lauded by fellow researchers for his theories regarding innovative cancer treatments, as well as anti-aging research.
In fact, he is considered one of the foremost experts in cellular differentiation ( a process where a cell changes from one cell type to another) and molecular biology. Additionally, Blagosklonny has been praised for his insights regarding the genesis of cancer in the human body. The ability to identify what causes cancer is paramount to helping not only treat, but also eradicate the disease, and Blagosklonny’s research is undoubtedly moving oncology research in that direction. In addition to his work in oncology and anti-aging, Mikhail Blagosklonny is also an author; he has published over 180 articles on the topic of cancer and how certain drug therapies impact patients. He has also co-authored several books where he has chronicled various research reviews. Blagosklonny has edited works for Oncotarget and several other publications like Cancer Biology and Therapy, which publishes research that delineates the molecular basis of cancer. He also performs editing work for Aging Journals and Cell Cycle. Additionally, Blagosklonny is a member of the editorial board for Cell Death and Differentiation, which is a publication that examines the relationship between molecular biology, cell biology, and biochemistry as they relate to cell death and differentiation.